By Dr Demi Signer · Medically reviewed by Dr Gerald Hoffman, MD / PharmD · Updated August 2026 · For educational and research purposes · 18+

Quick Answer

CJC-1295 and Ipamorelin are a popular research peptide combination studied for stimulating the body’s own growth hormone. CJC-1295, a GHRH analog, provides a steady background signal, while Ipamorelin, a selective ghrelin mimetic, triggers clean GH pulses with little effect on hunger or cortisol. Together they are studied for lean body mass, recovery, fat loss, and sleep. The most common research form pairs CJC-1295 No-DAC with Ipamorelin. These peptides are sold for research use only, are not FDA-approved for human use, and are banned in sport.

Key Takeaways

• The stack pairs CJC-1295, a steady GHRH signal, with Ipamorelin, a clean GH pulse.
• DAC vs No-DAC: No-DAC (Mod GRF 1-29) is short-acting, while DAC lasts for days.
• Studied for GH and IGF-1 increases, lean mass, recovery, fat loss, and sleep.
• Not FDA-approved, sold research-use-only, and banned by WADA.
• The pituitary response is well-documented in research; human body-composition data is still emerging.

What Is the CJC-1295 + Ipamorelin Stack?

CJC-1295 and Ipamorelin are two growth-hormone secretagogues that researchers study together because their mechanisms complement one another. One raises the baseline signal for growth hormone (GH), and the other adds a sharp, clean pulse on top of it. That pairing is the whole idea behind the stack. Neither peptide is a hormone itself, but both are signals that ask the pituitary to do more of its own job, which is a key reason they read differently from taking growth hormone directly.

To see why it works, it helps to picture the GH axis. The hypothalamus sends GHRH to the pituitary gland, the pituitary releases GH, and GH prompts the liver to produce IGF-1, the messenger behind much of GH’s downstream activity. This release is rhythmic and pulses hardest during deep sleep. CJC-1295 and Ipamorelin are studied as two different ways to nudge that natural system. Because the two enter at different points, GHRH and the ghrelin receptor, researchers can study each lever on its own or combined. That flexibility is part of why the pairing shows up so often in the literature and in community protocols.

This is actually a research combination, not a prescribed therapy. The compounds are sold for laboratory research, and below we describe what the science and community report, with citations, to give research context in place of a treatment plan.

How CJC-1295 Works (GHRH Analog)

CJC-1295 is a modified version of GHRH, the hormone that tells the pituitary to release GH. The modifications make it far more stable than natural GHRH, so where natural GHRH fades in minutes, this version keeps signaling for much longer. That extended signal is its defining feature.

In healthy adults, a single subcutaneous injection of CJC-1295 produced dose-dependent GH increases of 2- to 10-fold for 6 days or more, with a measured half-life of 5.8 to 8.1 days (Teichman et al., 2006). That long half-life comes from the DAC modification, covered in detail below. In plain terms, CJC-1295 raises the background level of GH signaling and holds it there. 

The original GHRH molecule is fragile and clears almost immediately, so the value of the modified analog is durability: one signal that keeps working across days. That durability is also what separates the DAC and No-DAC forms, since the DAC modification is what extends the half-life so dramatically.

How Ipamorelin Works (Selective Ghrelin Mimetic / GHRP)

Ipamorelin is a growth-hormone-releasing peptide (GHRP) that mimics ghrelin at the pituitary. Where CJC-1295 provides a steady signal, Ipamorelin triggers a short, sharp pulse of GH release, closer to the way the body naturally spikes GH.

Its standout trait is selectivity. Ipamorelin was described as the first selective GH secretagogue, releasing GH without the rise in ACTH, cortisol, or prolactin seen with older peptides like GHRP-6 and GHRP-2 (Raun et al., 1998). That clean profile, GH up with hunger and stress hormones largely undisturbed, is the reason it became the preferred GHRP for research pairings. 

Older GHRPs could raise appetite and cortisol enough to muddy a study, which made isolating a pure GH effect harder. Ipamorelin’s selectivity is precisely why it slots so neatly alongside a GHRH analog, since it adds the pulse with minimal noise.

How CJC-1295 and Ipamorelin Work Together (The Synergy)

The synergy is a steady signal plus clean pulse model. CJC-1295 increases the baseline of GH signaling, and Ipamorelin adds amplitude on top with a sharp pulse. Because they act through two different receptors, the GHRH receptor and the ghrelin receptor, the combined GH response is fuller and more physiological than either peptide produces alone.

Think of it like a sound system. CJC-1295 turns up the background level, while Ipamorelin hits the sharp note. Acting together at the same time, they push the pituitary through two doors at once, which is why researchers pair them for a fuller response than either produces solo.

One nuance most online resources don’t mention: GH secretion stays pulsatile even under continuous CJC-1295 stimulation (Ionescu & Frohman, 2006). The body keeps its rhythm, which is part of why timing and the natural nighttime peak still matter to researchers designing protocols. This detail also explains a common design choice: pairing a short No-DAC pulse with Ipamorelin to work with the body’s rhythm, so the added GH lands close to when the system would naturally release it.

CJC-1295 DAC vs No-DAC (Modified GRF 1-29)

The single most important distinction in this topic is DAC versus No-DAC, because it changes how the compound behaves entirely. The CJC-1295 DAC vs no DAC question is the one most researchers ask first, since the answer decides dosing frequency and pulse pattern. DAC stands for Drug Affinity Complex, a modification that lets CJC-1295 bind to albumin in the blood and stay active for days. No-DAC, often labeled Modified GRF 1-29, skips that and clears quickly.

No-DAC has a short half-life of roughly 30 minutes, so it produces a brief, natural-looking pulse and is dosed frequently. That short, pulse-like action is exactly why No-DAC is the form most often paired with Ipamorelin, since both create quick pulses that echo the body’s own rhythm. DAC, by contrast, binds albumin and stretches its half-life to days, which the Teichman data put at 5.8 to 8.1 days, giving a longer, more sustained GH signal with fewer injections.

The takeaway, No-DAC plus Ipamorelin is the standard research stack because both mimic natural pulses, while DAC suits research into a steady, extended GH signal. The trade-off is convenience against physiology. DAC means fewer injections and a smoother curve, while No-DAC means more frequent handling in exchange for a pattern that looks more like the body’s own. Which one a study uses depends on the question being asked.

Researched Benefits of CJC-1295 + Ipamorelin

The benefits below are framed as research observations and community reports, not guarantees, and the evidence behind each one varies in strength. The CJC-1295 Ipamorelin benefits most discussed online clusters around growth hormone, recovery, and sleep, so it helps to separate the well-supported from the merely popular.

• Higher GH and IGF-1. This is the best-documented effect. Teichman and colleagues recorded IGF-1 rising 1.5- to 3-fold for 9 to 11 days after a single CJC-1295 dose in healthy adults.
• Lean body mass and recovery. GH and IGF-1 are tied to tissue repair, so the stack is studied for recovery and lean-mass support. Human body-composition data for the blend specifically is still emerging.
• Fat loss and body composition. GH influences fat metabolism, which is why fat-loss interest is common. Direct controlled trials on the stack are limited.
• Sleep quality. GH release peaks during deep sleep, so improved sleep is a frequently reported subjective effect.
• Skin and connective tissue. General recovery and connective-tissue support come up in research discussion, with early evidence.

The GH and IGF-1 response is well-supported, while body-composition and cosmetic claims sit on thinner human evidence. A helpful way to frame it: the input, more GH and IGF-1, is measurable and repeatable, and the downstream outputs, fat, muscle, and skin, are where individual variation and thin trial data make firm promises impossible. That gap between mechanism and outcome is the honest center of this whole topic.

CJC-1295 + Ipamorelin Dosage & Protocol (Research Context)

There is no FDA-approved human dose for this stack, because it is not an approved drug. This section describes the general shape of protocols discussed in research and community settings, and it deliberately avoids publishing a self-injection recipe. A CJC-1295 Ipamorelin dosage search returns a flood of conflicting numbers, which is exactly why a supervising clinician, not a forum, should set any figure. Any specific figures circulating online (such as below) are unverified and should be set and supervised by the licensed clinician reviewing your case.

In the published Teichman research, subcutaneous CJC-1295 was administered at 30 to 60 micrograms per kilogram in a controlled clinical trial, which is a published study figure and carries no use recommendation. In practice, the No-DAC form is short-acting and therefore discussed as a frequent, often nightly protocol, typically fasted or before bed to align with the natural nighttime GH peak. The DAC form is longer-acting and discussed on a weekly-style cadence. Reconstitution follows the specific product’s documentation.

Treat the parts you can control, sourcing, storage, and documentation, as the priority, and leave dosing decisions to a qualified provider. One reason specifics are risky online is that microgram figures shift with body weight, goals, and the exact compound, and an unverified number copied from a forum can be meaningfully off. A supervising clinician can also order the bloodwork that shows whether a protocol is doing anything at all.

Results Timeline: How Long to See Changes

Reported changes arrive in stages. In the first days to weeks, the most common reports are better sleep and a sense of faster recovery, which fits GH’s role in deep sleep. Body-composition changes, when they occur, are described over 8 to 12 weeks or longer, since tissue change is slow.

IGF-1 is the useful objective marker here, because it shifts measurably early and can be tracked by bloodwork. That single lab value turns a vague sense of progress into something a researcher can chart, which is why it anchors serious protocols. A realistic before and after is gradual and individual, closer to steady week-over-week change than a dramatic transformation, and IGF-1 lab values give a far more reliable read than a mirror. 

Anyone studying the stack seriously watches the labs, not just the scale. It also helps to hold a baseline. An IGF-1 reading before starting gives every later value something to compare against, and it separates a real shift from normal day-to-day variation. Progress photos and subjective sleep notes add context, while the lab number stays the anchor.

CJC-1295 + Ipamorelin Side Effects & Safety

Reported side effects are usually mild and manageable, and they vary by individual. The CJC-1295 Ipamorelin side effects people report most often are local and temporary. 

• The common ones are injection-site reactions, water retention, tingling or numbness in the hands, a brief head-rush or flushing, headache, changes in insulin sensitivity or blood sugar, and occasional fatigue. 
• The Teichman trial reported no serious adverse reactions and described CJC-1295 as safe and relatively well tolerated in its studied context .

The larger risks lie outside the molecule. Because these peptides trade in an unregulated market, contamination and inconsistent purity are real concerns, which is why a batch-specific Certificate of Analysis matters so much. Anything that raises GH and IGF-1 also warrants caution for people with a personal history of cancer, since IGF-1 influences cell growth, and for anyone managing blood sugar or taking interacting medications. 

This stack is not appropriate without professional oversight, so speak with a licensed provider first. Blood sugar deserves a specific mention, since growth hormone can reduce insulin sensitivity, which matters for anyone prediabetic or diabetic. A provider can monitor that alongside IGF-1 and catch a problem early, which self-directed use cannot.

Is CJC-1295 a Steroid?

No. CJC-1295 is a peptide, specifically a GHRH analog, not an anabolic steroid. The mechanisms are completely different. Anabolic steroids add exogenous hormones like testosterone to the body, while CJC-1295 signals your own pituitary to release more of your own growth hormone.

That difference in mechanism means a different risk and effect profile, and it is why the two are studied and regulated separately. It also means CJC-1295 works within the body’s existing feedback systems. None of that makes it risk-free or approved, and it remains a research-use compound, but the steroid label is simply inaccurate.

Does CJC-1295 + Ipamorelin Affect Testosterone?

The stack acts primarily on the GH and IGF-1 axis, but not on testosterone directly. Its receptors are the GHRH receptor and the ghrelin receptor, neither of which is the testosterone pathway. Any effect on testosterone is indirect at most and not well established in research.

The practical read: do not expect this combination to function as a testosterone booster. People whose goal is testosterone typically look at different compounds and, more importantly, a proper clinical workup. CJC-1295 and Ipamorelin are a GH-axis story, and that is where the evidence sits.

Is CJC-1295 + Ipamorelin FDA-Approved? (Honest Answer)

Sadly, no. Neither CJC-1295 nor Ipamorelin is FDA-approved for human use, and both are sold for research use only. In October 2023, the FDA placed CJC-1295 and ipamorelin in the category of bulk drug substances that raise safety concerns for pharmacy compounding, which tightened the routes through which they had been accessed. Both are also on the WADA Prohibited List, so they are banned in sport at all times.

CJC-1295 + Ipamorelin is legally available, but only for research use, not human consumption. While this classification strictly distinguishes research-grade materials from products intended for human consumption, it ensures that these compounds remain accessible for valid experimental inquiry and the advancement of peptide science. 

It is NOT appropriate for minors, for people who are pregnant or nursing, or for anyone seeking a shortcut around approved medical care. Honesty here protects the reader more than any benefits list. 

The pharmacy compounding change is also worth understanding, because it narrowed a route through which some people previously obtained these peptides with clinical oversight. That has pushed more of the market toward unregulated suppliers, which raises the stakes on sourcing and testing considerably.

CJC-1295 vs Ipamorelin (How They Differ)

The two are often searched as rivals, though they are studied as teammates. The clearest way to hold the difference is mechanism and timing.

Alone, CJC-1295 lifts the baseline and Ipamorelin sharpens the pulse. Combined, they cover both halves of a natural GH release, which is why researchers stack them together far more often than they compare them as either-or. Choosing one alone is uncommon, since each covers only half the picture: baseline without pulse, or pulse without a raised baseline. For a fuller side-by-side, you can see the CJC-1295 vs Ipamorelin breakdown.

Stacking CJC-1295 + Ipamorelin (With Other Peptides)

In research discussion, this stack sometimes sits alongside other compounds, and it helps to understand the categories more than any single protocol. 

• Tesamorelin and Sermorelin are other GHRH-type peptides studied in the same GH lane.
• MK-677 is an oral GH secretagogue that comes up as a needle-free alternative in conversation.
• A separate category, the GLP-1 receptor agonists such as Tirzepatide and Semaglutide, works on appetite and metabolism in place of GH, so the two are studied for different questions. BPC-157 appears in recovery-focused discussion. 

Please note that this section is informational only. It describes how researchers come up with these combinations, and it is not a protocol recommendation. Every one of these carries its own regulatory status and risk profile, and stacking multiplies the sourcing and safety questions. The more compounds in a protocol, the harder it becomes to attribute any effect, or any side effect, to a single one. That is a real drawback of complex stacks in a research setting, where isolating variables is the whole point.

What the Research Says

The strongest evidence sits with the individual peptides. In two randomized, placebo-controlled trials, subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults and was safe and relatively well tolerated (Teichman et al., 2006). That paper, cited well over a hundred times, is the anchor for the GH and IGF-1 claims.

On the Ipamorelin side, foundational research established it as the first selective GH secretagogue, raising GH without the cortisol and prolactin bumps of earlier GHRPs (Raun et al., 1998). And follow-up work showed GH keeps its pulsatile rhythm even under continuous CJC-1295 signaling (Ionescu & Frohman, 2006).

The gap: there are few long-term, human, randomized trials on the specific stack for body composition. The mechanism is well-mapped, and the downstream, real-life outcomes are still thinly studied. Much of the human GH and IGF-1 data comes from small, short trials or from GH-deficient populations, so generalizing to healthy adults chasing body composition calls for real caution. That is the honest state of the evidence: a strong signal on the biochemistry, and open questions at the finish line.

What Reddit & Practitioners Say

Community discussion is candid, and a few themes repeat across spaces like r/Peptides and physician creators on YouTube. Treat all of it as anecdote to weigh, but not medical advice.

The most common protocol talk centers on No-DAC plus Ipamorelin dosed nightly and fasted, with ongoing debate about exact timing around sleep. “Bloodwork beats bro-science” is a recurring refrain, with experienced users pushing others to track IGF-1 for a real answer. Sourcing and purity come up constantly, often with people swapping COA screenshots. Expectations skew realistic, with veterans describing gradual change and warning against hype. And stacking questions, especially alongside GLP-1s, are among the most frequent threads. 

A recurring caution from more experienced voices is to change one variable at a time, so that a result can actually be traced to a cause. The overall tone leans skeptical of dramatic claims and heavy on documentation, which is a healthy signal in an unregulated space.

Where to Source Research-Grade CJC-1295 + Ipamorelin

Sourcing is where most of the real risk exists, so the checklist is considerably more important than any marketing you’ll see online. When we compared 40+ research suppliers, the ones worth considering shared the same signals: a batch-specific Certificate of Analysis, HPLC and mass-spectrometry purity verification at 99% or higher, clear lot and product labeling, transparent research-use-only positioning, and lot-by-lot testing.

Across the suppliers we weighed on those criteria, Cellugenix came out on top for documentation and traceability, with accessible COAs and clear labeling. The reason the COA sits at the top of the checklist is simple: in an unregulated market, the label is a claim and the batch report is the evidence. A supplier that cannot produce a lot-specific analysis for the exact vial you are buying leaves purity and identity unproven. Purity verified by HPLC and identity confirmed by mass spectrometry are the two data points worth insisting on.

Frequently Asked Questions

What is CJC-1295 + Ipamorelin used for?

In research settings it is studied for raising growth hormone and IGF-1, and it is associated with recovery, lean body mass, fat loss, and sleep quality. The GH and IGF-1 response is well-documented, while body-composition outcomes rest on thinner human evidence. It is a research-use compound, not an approved therapy.

Is CJC-1295 a steroid?

No, CJC-1295 is a peptide and a GHRH analog that signals the body to release its own growth hormone. Anabolic steroids add exogenous hormones instead. The mechanisms, effects, and regulation differ, though CJC-1295 is still not risk-free or FDA-approved.

Does it affect testosterone?

It acts mainly on the growth hormone and IGF-1 axis, not on testosterone directly. Any testosterone effect is indirect and not well established, so it should not be expected to work as a testosterone booster. Goals centered on testosterone call for a different approach and a clinical workup.

How long to see results?

Sleep and recovery are often reported within days to weeks, while body-composition changes, when they occur, take 8 to 12 weeks or longer. IGF-1 shifts are measurable early through bloodwork, which is the most objective way to track a response.

DAC vs No-DAC, which is used?

No-DAC (Mod GRF 1-29) is short-acting and produces natural-style pulses, which makes it the common pairing with Ipamorelin. DAC binds albumin and lasts for days, giving a longer, steadier signal with fewer injections.

Is it FDA-approved?

No, neither peptide is FDA-approved for human use, both are sold research-use-only, and the FDA flagged them for compounding restrictions in 2023. Both are also banned in sport under the WADA Prohibited List.

What are the side effects?

Commonly reported effects include water retention, tingling, injection-site reactions, flushing, headache, and changes in blood sugar. The bigger concern is unregulated sourcing, so buy only COA-tested material and consult a licensed provider before considering use.

The Bottom Line

CJC-1295, a steady GHRH signal, and Ipamorelin, a clean GH pulse, are studied together for growth hormone and IGF-1, recovery, lean mass, and sleep. No-DAC is the common form for pairing with Ipamorelin, and the evidence is promising but still early, strong for the GH and IGF-1 response and noticeably thinner for body composition. They are research-use-only, not FDA-approved, and banned by WADA. 

Consider only third-party tested peptides with batch-specific COA, keep expectations realistic and lab-tracked, and consult a licensed provider before considering use. These compounds are legally available for research use only. We recommend approaching them with curiosity, clear documentation, and professional oversight, rather than using them as a substitute for standard medical care.

Disclaimer

This article is for educational and research purposes only and is not medical advice. CJC-1295 and Ipamorelin are not FDA-approved for human use, are sold for research use only, and are banned by WADA. They are not intended to diagnose, treat, cure, or prevent any disease. Potential risks include water retention, blood-sugar changes, and contamination from unregulated products. Consult a licensed healthcare provider before considering any peptide. 18+.

Related posts:

How Advanced Nursing Roles Are Improving Patient Care Outcomes 6 Best Remineralizing Toothpaste For Enamel Repair: Picks for Sensitive Teeth, Receding Gums, and Early Erosion How Healthcare Is Evolving to Meet Modern Patient Needs 5 Best 9mg Nicotine Pouches Online: The Complete Buyer’s Guide How Motion-Tracking Gadgets Improve Physical Therapy Accuracy Buy BPC-157 Peptide: Dosage, Side Effects, and How To Get BPC-157 Products in 2026

Stay updated, free articles. Join our Telegram channel

Join